

LAC+USC Medical Center

Public Reporting of Outcomes


Treatment of Lung Cancer at LAC+USC Medical Center

Treatment of patients with mediastinal lymph node positive disease

- For patients with non small cell lung cancer, clinically positive lymph nodes in the mediastinum (N2), should not be resected as primary therapy (NCCN v2. 2017).
- The COC standard is 85%.
- LAC+USC Medical Center continues to exceed this standard in 2014 and 2015.

Timeliness of administration of systemic therapy in patients with non small cell lung cancer

- Some patients that have had all of their disease recovered by surgery should get chemotherapy (NCCN v2. 2017).
- The Commission on Cancer's standard is to give this adjuvant therapy within 4 months prior to surgery or 6 months after surgery. The compliance standard for CoC institutions is 85%.
- LAC+USC Medical Center and clinics continue to meet or exceed this standard in 2014 and 2015.

Select Measures	Measure	CoC Std / % ▲	Estimated Performance Rates (%)				Review
			2012	2013	2014	2015	
Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic lymph node-positive (pN1) and (pN2) NSCLC (Quality Improvement)	LCT	4.5 / 85%	no data	100.00	100.00	100.00	
Surgery is not the first course of treatment for cN2, M0 lung cases (Quality Improvement)	LNoSurg	4.5 / 85%	100.00	100.00	100.00	85.70	